Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Exacis Develops mRNA-Engineered iPSC-Derived NK Cells for Difficult-To-Treat Tumors

americanpharmaceuticalreviewApril 01, 2021

Tag: Exacis , ExaNK , iPSC , mRNA

PharmaSources Customer Service